Class: Use (241)
Patent Number: 6750196
This patent teaches expansion of retinal cells, and stem cells thereof, through the administration of proteins called neuroregulins. The patent is useful for treatment of a variety of ocular degenerative diseases.
Inventors: Reh, Thomas A. (Seattle, WA); Marchionni, Mark A. (Arlington, MA); McCabe, Kathryn L. (Seattle, WA); Bermingham-McDonogh, Olivia (Watertown, MA); Mahanthappa, Nagesh K. (Cambridge, MA); Gwynne, David I. (Beverly, MA)
Assignee: Acorda Therapeutics (Hawthorne, NY)
Date of First Priority Issue: Monday March 27th, 1995
Patent Number: 6214369
This patent covers the use of mesenchymal stem cells for generation of bone and cartilage. It is interesting that Osiris has patents in this area as well.
Inventors: Grande, Daniel A. (Sea Cliff, NY); Lucas, Paul A. (Macon, GA)
Assignee: MorphoGen Pharmaceuticals, Inc. (Downey, CA)
Date of First Priority Issue: Tuesday March 14th, 1995
Patent Number: 5906934
This patent covers the use of mesenchymal stem cells for generation of artificial bone and cartilage. It is interesting that this patent was issued in light of Osiris's domination of the field of mesenchymal stem cells. This patent should be read in light of the other mesenchymal stem cell patents.
Inventors: Grande, Daniel A. (Sea Cliff, NY); Lucas, Paul A. (Macon, GA)
Assignee: Morphogen Pharmaceuticals, Inc. (New York, NY) North Shore University Hospital Research Corporation (Manhasset, NY)
Date of First Priority Issue: Tuesday March 14th, 1995
Patent Number: 6110743
This patent covers islet stem cells and cell lines that generate islet cells. This patent could be useful for the treatment of type 1 diabetes. In some cases, it may be beneficial to encapsulate the cell lines so as to avoid immune mediated rejection. Alternatively these cells would provide a great source of tissue for using the Edmonton Protocol.
Inventors: Levine, Fred (Del Mar, CA); Wang, Sijian (Dallas, TX); Beattie, Gillian M. (Poway, CA); Hayek, Alberto (La Jolla, CA)
Assignee: The Regents of the University of California (Oakland, CA) Whittier Institute for Diabetes and Endocrinology (La Jolla, CA)
Date of First Priority Issue: Friday February 10th, 1995
Patent Number: 5980886
This patent covers ways of transfecting liver cells in vivo through the induction of liver stem cell activation by first transfection with a gene such as tPA or uPA, and then once the cells are proliferating, transfection with another gene that is therapeutic.
Inventors: Kay, Mark A. (Seattle, WA); Lieber, Andre (Seattle, WA)
Assignee: University of Washington (Seattle, WA)
Date of First Priority Issue: Wednesday December 14th, 1994
Patent Number: 7,341,719
One of the regenerative cells of the muscle is the myoblast. These cells essentially act as muscle stem cells, having the ability to multiply after injury and form muscle by fusing with other myoblasts. Myoblasts are very practical for cell therapy since they may be easily extracted from autologous sources and grown in vitro. Additionally, there is some evidence that myoblasts, upon fusing...
Inventors: Law; Peter K. (Memphis, TN)
Assignee: None Stated
Date of First Priority Issue: Tuesday December 13th, 1994
Patent Number: 5962321
This patent teaches the use of the cytokine LIF for increasing the rate of implantation of embryos. This patent is useful for generation of knockout and transgenic mice.
Inventors: Gough, Nicholas Martin (North Balwyn, AU); Willson, Tracey Ann (North Balwyn, AU); Seamark, Robert Frederick (Beulah Park, AU)
Assignee: Amrad Corporation Limited (Victoria, AU)
Date of First Priority Issue: Thursday December 1st, 1994
Patent Number: 6068836
This patent teaches how to transfect quiescent hematopoietic stem cells. Transfection of these primitive stem cells should be useful for a variety of gene therapy applications including treatment of several metabolic diseases such as Krabbe Disease.
Inventor: Quesenberry, Peter J. (Shrewsbury, MA)
Assignee: University of Massachusetts (Boston, MA)
Date of First Priority Issue: Wednesday November 23rd, 1994
Patent Number: 6019965
This patent teaches that the administration of the clinically-used cytokine GM-CSF is useful for the treatment of alveolar proteinosis. This patent would be great to use in combination with systemically administered stem cell therapy since most stem cells given intravenously end up in either the lung or the liver.
Inventors: Dunn, Ashley Roger (Parkville, AU); Stanley, Edouard Guy (London, GB); Lieschke, Graham John (Parkville, AU); Grail, Dianne (Parkville, AU); Fowler, Kerry J. (Parkville, AU)
Assignee: Ludwig Institute for Cancer Research (New York, NY)
Date of First Priority Issue: Monday October 24th, 1994
Patent Number: 5972703
This patent teaches the isolation, expansion, and use of bone stem cells that are separated from bone marrow cells.
Inventors: Long, Michael W. (Northville, MI); Mann, Kenneth G. (Shelburne, VT)
Assignee: The Regents of the University of Michigan (Ann Arbor, MI)
Date of First Priority Issue: Friday August 12th, 1994